Working… Menu
Trial record 49 of 173 for:    pertuzumab

Her2-positive Lung Cancer Treated With Dedicated Drug (R2D2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03845270
Recruitment Status : Recruiting
First Posted : February 19, 2019
Last Update Posted : September 2, 2019
Information provided by (Responsible Party):
Intergroupe Francophone de Cancerologie Thoracique

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : December 2020
Estimated Study Completion Date : March 2022